Table 2

EAIRs (95% CI) of IBD over the entire treatment period for patients taking any dose of secukinumab

PsO Studies
N=5181
PsA Studies
N=1380
AS Studies
N=794
Median exposure
(min–max), days
505.0 (1–1825)1067.5 (8–1827)981.5 (1–1530)
Total exposure, PY10 416.93866.91943.1
Incidence, identified by standard definition (preferred term)
 CD, EAIR per 100 PY
 (95% CI)
0.05 (0.02 to 0.11)0.08 (0.02 to 0.23)0.4 (0.2 to 0.8)
 UC, EAIR per 100 PY
 (95% CI)
0.13 (0.07 to 0.23)0.08 (0.02 to 0.23)0.2 (0.1 to 0.5)
 IBDU, EAIR per 100 PY (95% CI)0.01 (0.00 to 0.05)0.05 (0.01 to 0.19)0.1 (0.0 to 0.3)
  • EAIR data are displayed to two decimals where N>1000; if N<1000, then data are displayed to one decimal.

  • AS, ankylosing spondylitis; CD, Crohn’s disease; EAIR, exposure-adjusted incidence rate; IBD, inflammatory bowel disease; IBDU, IBD-unclassified; PY, patient-years; PsA, psoriatic arthritis; PsO, psoriasis; UC, ulcerative colitis.